Jens Eckstein
Director/Board Member at IMUGENE LIMITED
Net worth: 1 M $ as of 30/03/2024
Profile
Jens W.
Eckstein is currently the Chairman & Chief Executive Officer at Samsara Therapeutics, Inc. He is also a Non-Executive Director at Imugene Ltd., a Director at Palleon Pharma, Inc., Aeovian Pharmaceuticals, Inc., Cleara Biotech BV, and HAYA Therapeutics SA. Additionally, he is the Managing Partner at Apollo Ventures Holding GmbH.
In the past, Dr. Eckstein served as the President & Chief Executive Officer at SelectX Pharmaceuticals, Inc. He was also a Director at PPD Dermatology LLC, Concert Pharmaceuticals, Inc., Rapid Micro Biosystems, Inc., Alios BioPharma, Inc., Anchor Therapeutics, Inc., Enanta Pharmaceuticals, Inc., Thrasos Therapeutics, Inc., Biohealth Innovation, Inc., and Action Potential Venture Capital.
Furthermore, he held positions as a Director at ZappRx, Inc., Gladius Pharmaceuticals Corp., Decibel Therapeutics, Inc., Palleon Pharmaceuticals, Inc., and served as an Advisor at Sirtris Pharmaceuticals, Inc. He was the President of GSK Equity Investments Ltd.
and worked as a Principal at GPC Biotech, Inc. He also served as a Venture Partner at TVM Capital Corp.Dr. Eckstein obtained a doctorate degree from Harvard University and Universität Konstanz.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMUGENE LTD
0.28% | 11/01/2024 | 20,738,095 ( 0.28% ) | 1 M $ | 30/03/2024 |
Jens Eckstein active positions
| Companies | Position | Start |
|---|---|---|
| IMUGENE LIMITED | Director/Board Member | 19/05/2019 |
Apollo Ventures Holding GmbH
 Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | Private Equity Investor | 31/05/2019 |
Cleara Biotech BV
 Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | Director/Board Member | 26/09/2022 |
Aeovian Pharmaceuticals, Inc.
 Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Director/Board Member | - |
Samsara Therapeutics, Inc.
 Samsara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE. | Chief Executive Officer | - |
Palleon Pharma, Inc.
 Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Director/Board Member | - |
HAYA Therapeutics SA
 HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Director/Board Member | - |
Former positions of Jens Eckstein
| Companies | Position | End |
|---|---|---|
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | President | 30/06/2019 |
Action Potential Venture Capital
 Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | Director/Board Member | 30/04/2019 |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Jens Eckstein
| Harvard University | Doctorate Degree |
| Universität Konstanz | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| RAPID MICRO BIOSYSTEMS, INC. | Producer Manufacturing |
| IMUGENE LIMITED | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private companies | 21 |
|---|---|
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
PPD Dermatology LLC
 PPD Dermatology LLC Pharmaceuticals: MajorHealth Technology PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA. | Health Technology |
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
SelectX Pharmaceuticals, Inc.
 SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Health Technology |
TVM Capital Corp.
 TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Finance |
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Finance |
Action Potential Venture Capital
Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | Finance |
ZappRx, Inc.
 ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Commercial Services |
Gladius Pharmaceuticals Corp.
 Gladius Pharmaceuticals Corp. BiotechnologyHealth Technology Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE. | Health Technology |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | Finance |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Health Technology |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Health Technology |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |
Samsara Therapeutics, Inc.
Samsara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Samsara Therapeutics, Inc. operates as a biopharmaceutical platform company. It engages in the development and commercialization of first-in-class therapeutics for the treatment of unmet medical needs and age-related diseases. The company was founded by Sebastian Aguiar in 2018 and is headquartered in Lewes, DE. | Health Technology |
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | Health Technology |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Jens Eckstein
